Alterity Therapeutics (NASDAQ:ATHE) announced on Monday that it has received positive written feedback from the U.S. Food and Drug Administration (FDA) following a second Type C meeting regarding its ATH434 Phase 3 program.
The meeting focused on the clinical development of ATH434 for the treatment of Multiple System Atrophy (MSA), a rare and debilitating neurodegenerative disorder.
The FDA’s feedback specifically provided support for the program’s Chemistry, Manufacturing, and Control (CMC) elements.
This regulatory alignment is a critical step for late-stage development, as it validates the company’s manufacturing processes and quality controls as sufficient for a Phase 3 trial.
Alterity confirmed that its manufacturing scale-up is currently progressing in line with these validated protocols.
This latest interaction follows an earlier Type C meeting that addressed non-clinical and clinical pharmacology topics, further clarifying the regulatory requirements for the upcoming pivotal study.
With these technical milestones addressed, Alterity remains on track for an End-of-Phase 2 meeting in mid-2026.
That session will serve as the final formal gate before the company initiates its Phase 3 program.
ATH434 is designed to inhibit the aggregation of pathological proteins and rescue nerve cells from iron-induced oxidative stress, potentially offering a first-in-class disease-modifying therapy for MSA patients who currently have no approved treatment options.